Der p2‑A20 DNA vaccine attenuates allergic inflammation in mice with allergic rhinitis.

ABSTRACT: Allergic rhinitis (AR) is a common disease that requires more convenient, safe and effective antigen‑specific immunotherapies. The present study aimed to investigate the therapeutic effect of intranasal administration of a eukaryotic expression vector co‑expressing Der p2 and A20 protein (pVAX1‑Der p2‑A20) on mice with allergic rhinitis. The pVAX1‑Der p2‑A20 vaccine was prepared and encapsulated into poly(L‑lactide‑co‑glycolide) (PLGA) nanoparticles. An allergic rhinitis Balb/c mouse model was established through intraperitoneal sensitization with recombinant Der p2 and cholera toxin followed by intranasal challenge with recombinant Der p2. The treatment effect of the DNA vaccine on nasal allergic inflammation was evaluated, and serum IgE, sIgE, IgG and cytokine levels were determined by E

SUBMITTER: Hu W 

PROVIDER: S-EPMC6854600 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature